Back to search

Aristotle University Of Thessaloniki (AUTH)

Ανάπτυξη καινοτόμων φαρμακομορφών για τη βελτιωμένη χορήγηση φλαβονοειδών

Abstract

dc:description

In the present doctoral dissertation, the development of innovative pharmaceutical formulations for the improved administration of flavonoids was studied. Luteolin was selected as the active pharmaceutical ingredient, as a major representative of the class due to its multifaceted bioactivity and physicochemical properties. Luteolin exhibits low aqueous solubility and reduced bioavailability, similar to most flavonoids, presenting significant challenges during its formulation. In this context, the techniques of “Amorphous Solid Dispersions (ASD)” and “Deep Eutectic Solvents (DESs)” were employed as modern formulation methods to increase the solubility of luteolin (LUT), in order to produce final effective dosage forms. Furthermore, its administration within the oral cavity (buccal or topical) was investigated as a proposed approach, by developing and evaluating gel systems. In the first part of the research, after the thermophysical characterization of the active substance, solid dispersions (SDs) of luteolin were prepared using semicrystalline and amorphous polymeric carriers. Polyethylene glycol (PEG) and Poloxamer 188 (P188) were initially selected, with melt and solvent evaporation techniques used for the preparation of the SDs. The use of differential scanning calorimetry (DSC) and scanning electron microscopy (SEM) indicated the amorphization of the active substance within the SDs, a finding that was also confirmed by powder X-ray diffraction (pXRD) patterns. Additionally, attenuated total reflectance Fourier-transform infrared spectroscopy (ATR-FTIR) showed the existence of molecular interactions between the active substance and the polymeric carrier. Finally, the in vitro drug release profile study in simulated saliva fluid (SSF) demonstrated that these systems provided higher solubility levels compared to crystalline luteolin. Subsequently, regarding the formulation using amorphous polymeric carriers, the appropriate carrier was initially selected (screening) using two different methods (“film casting” and “solvent shift”), in order to inhibit recrystallization of the active substance and prevent its precipitation in the dissolution medium. Polyvinylpyrrolidone (PVP) emerged as the optimal carrier, being fully miscible with the active substance. Afterwards, the complete amorphization of LUT within the LUT-PVP SDs, as well as the stability of the systems for three months, was demonstrated via pXRD. Concurrently, molecular dynamics (MD) simulations and the use of ATR-FTIR spectroscopy proved the presence of strong intermolecular hydrogen bonds between luteolin and PVP, which stabilize the final systems. In vitro dissolution studies in simulated saliva fluid (SSF) confirmed the enhancement of solubility through ASDs, reaching up to six times higher levels compared to the crystalline drug. In the second part of the thesis, the evaluation of DES pharmaceutical formulations was attempted. Specifically, after the preparation of various systems, using choline chloride (ChCl) as a hydrogen bond acceptor (HBA) and examining different components as hydrogen bond donors (HBD), the stable DESs were subjected to solubility tests. The latter proved that all examined systems significantly increased the solubility of luteolin, with the greatest enhancement observed in glycerol (Gly)-based systems, particularly in those with molar ratios of ChCl:Gly (1:2) (DESA) and ChCl:Gly (1:3) (DESB). The thermal stability of these systems up to approximately 150°C was demonstrated through thermogravimetric analysis (TGA), confirming their suitability for thermal processing (such as tablet or capsule formation using wet granulation). Finally, ATR-FTIR spectroscopy and especially molecular modeling studies proved the presence of strong molecular interactions both among the individual components of the DES and with LUT. In the final part of the dissertation, a comparative study of ASDs (incorporated into a suitable gel system) and DES systems was conducted. In vitro drug release profile tests, using vertical Franz diffusion cells, showed enhanced solubility of the active substance in nearly all cases. Simultaneously, the suitability of these systems for intraoral administration was demonstrated, as they exhibit pseudoplastic flow behavior. Additionally, in vitro cell viability and anti-inflammatory activity studies on a gingival cell line confirmed the absence of cytotoxicity for all systems and the preservation of luteolin’s pharmacological activity. In fact, in the case of DES, an enhancement of the anti-inflammatory activity was observed, attributed to the presence of choline chloride in the systems. Finally, ex vivo permeability studies on porcine buccal tissue demonstrated a significant increase in luteolin retention within the tissue. In conclusion, the present doctoral dissertation highlighted the potential of modern formulation techniques (such as ASDs and DESs) to substantially enhance the solubility of luteolin, thereby contributing to the improved pharmaceutical exploitation of flavonoids. The final dosage forms developed exhibited stability, improved in vitro performance, and suitability for oral administration (buccal or topical), thanks to their favorable rheological and pharmaceutical properties. Particular emphasis should be placed on the DES systems, where the presence of choline chloride appears to contribute significantly not only in enhancing the solubility of the active substance but also in enhancing its anti-inflammatory activity through a synergistic mechanism. However, further in vivo studies are required for the comprehensive evaluation of the safety, bioavailability, and therapeutic efficacy of the proposed pharmaceutical formulations.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Koromili, Maria
  • Κορομηλή, Μαρία

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/60118

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Koromili, Maria; Κορομηλή, Μαρία. Ανάπτυξη καινοτόμων φαρμακομορφών για τη βελτιωμένη χορήγηση φλαβονοειδών. Aristotle University Of Thessaloniki (AUTH), 2025. http://hdl.handle.net/10442/hedi/60118